Weight management app Noom has revealed a major update to its GLP-1 Companion service to accompany and optimize popular GLP-1 drug therapies, which can cause temporary and long-term side effects like critical nutritional gaps and muscle loss. Aligning with the US FDA’s draft guidance, Noom offers tailored tools and content to support improved patient outcomes as a companion app for weight loss medications. “The label on GLP-1 medications says they are to be used ‘in combination with a reduced-calorie diet and increased physical activity,’” says Noom CEO Geoff Cook.
